Two months ago, a Senate report suggested that Insys Therapeutics (INSY) provided $2.5 million to a patient advocacy group in order to influence usage and providing of its Subsys opioid painkiller. The link, however, was not fully explored, but a new essay in a bioethics blog takes us a step closer to understanding how that relationship may benefit the company.

To do so requires a familiar exercise: follow the money. But it also helps to understand why Subsys and a handful of similar powerful medications, all of which are forms of fentanyl, are often favored by doctors for treating so-called breakthrough cancer pain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy